About

We focus on translating new findings into clinical practice and discovering innovative ways to use technology to improve diabetes care.
Affiliation
people
Faculty Position
  • Bergenstal, Richard M., MD, Medical Director, International Diabetes Center 1983 -
  • Carlson, Anders L., MD, Executive Director, International Diabetes Center 2015 -
  • Criego, Amy B., MD, MS, Medical Director, International Diabetes Center
  • Martens, Thomas W., MD, FACP, Medical Director, International Diabetes Center 2015 -
  • Passi, Rebecca A., Director of Research and Administration, International Diabetes Center
  • Simonson, Gregg D., Director, Care Transformation & Training
  • Willis, Holly J., PhD, RDN, LD, CDCES, Research Investigator
    • Publications While At HealthPartners
    selected publications
    Journal Article
  • A multicenter study of an investigational extended wear insulin infusion set in adults with type 1 diabetes. 
    Diabetes Technology & Therapeutics. 2026
  • A pragmatic intervention to increase screening of high-risk individuals for diabetic retinopathy. 
    Journal of Primary Care & Community Health. 2026
  • Adjunctive treatment with GLP-1 and dual GLP-1/GIP receptor agonists for people with type 1 diabetes: consensus report and practical guidelines for safe use. 
    Diabetes Technology & Therapeutics. 2026
  • Assessing the financial sustainability of a virtual clinic providing comprehensive diabetes care. 
    Journal of Diabetes Science and Technology. 2026
  • CGM-derived efficacy and overall safety of once-weekly insulin efsitora alfa (efsitora) relative to day of administration in adults with type 2 diabetes. 
    Diabetes, Obesity & Metabolism. 2026
  • Classification and regression tree analysis to understand theory-aligned barriers to glucose self-monitoring behaviors among insulin-using type 2 diabetes patients without continuous glucose monitors. 
    Journal of Health Psychology. 2026
  • Comparative safety of glucose-lowering medications on depression in adults with type 2 diabetes. 
    Diabetes, Obesity & Metabolism. 2026
  • Comparison of the continuous glucose monitoring profiles of four glucose-lowering medications in the GRADE randomized trial. 
    Diabetes care. 2026
  • Duration and characteristics of hypoglycemia with once-weekly insulin efsitora alfa versus once-daily basal insulins in adults with type 2 diabetes: exploratory safety analysis of QWINT 2-4. 
    Diabetes Research and Clinical Practice. 2026
  • Early consideration of automated insulin delivery in type 2 diabetes: a critical review. 
    Endocrine Practice. 2026
  • Evaluation of overall health state, treatment burden, and satisfaction with insulin efsitora alfa (efsitora) vs. daily comparator in adults with type 2 diabetes in the QWINT Clinical Trial Program. 
    Diabetes Therapy. 2026
  • Glycaemic metrics improve significantly within 7 days of continuous glucose monitoring initiation in non-insulin-using people with type 2 diabetes. 
    Diabetes, Obesity & Metabolism. 2026
  • Impact of automated insulin delivery on type 2 diabetes measures. 
    American Journal of Managed Care. 2026
  • Older adults benefit from virtual support for continuous glucose monitor use but require longer visits. 
    Journal of Diabetes Science and Technology. 2026
  • Percent time below range is strongly associated with clinically important level 2 hypoglycemia events in individuals with type 1 diabetes. 
    Diabetes Technology & Therapeutics. 2026
  • Predicting the complex, multilevel ecology of US county-level diabetes prevalence: a cross-sectional, artificial intelligence analysis. 
    Diabetes/Metabolism Research and Reviews. 2026
  • Real-world ketone testing patterns among people using FreeStyle Libre. 
    Diabetes Technology & Therapeutics. 2026
  • Safety and effectiveness of MiniMed™ 780G Advanced Hybrid Closed-Loop use with ultrarapid insulin lispro-AABC in pediatric and adult type 1 diabetes. 
    Diabetes Technology & Therapeutics. 2026
  • Safety and glycemic outcomes of the MiniMed 780G System with a disposable all-in-one sensor. 
    Diabetes Technology & Therapeutics. 2026
  • Staging prediabetes and type 2 diabetes: the time to start is now. 
    The lancet. Diabetes & endocrinology. 2026
  • The glucose monitoring comparison in primary care study (GluCoCare): study design, methods, recruitment success, and baseline characteristics of study participants. 
    Contemporary Clinical Trials. 2026
  • The importance of expanding medicare continuous glucose monitoring coverage for high-risk hypoglycemia. 
    Diabetes Technology & Therapeutics. 2026
  • Updated glucose management indicator (GMI) better aligns with HbA(1c) than current GMI: implications for clinical practice and reporting. 
    Diabetologia. 2026
  • Using Nutrition to Improve Time in rangE (UNITE): a randomized clinical trial with continuous glucose monitoring in people with type 2 diabetes not taking insulin. 
    Diabetes Technology & Therapeutics. 2026
  • "Now I can see it works!" Perspectives on using a nutrition-focused approach when initiating continuous glucose monitoring in people with type 2 diabetes: qualitative interview study. 
    JMIR diabetes. 2025
  • A call-to-action to eliminate barriers to accessing automated insulin delivery systems for people with type 1 diabetes. 
    Diabetes Technology & Therapeutics. 2025
  • A nutrition-focused approach during continuous glucose monitoring initiation in people with type 2 diabetes: using a theoretical framework to unite continuous glucose monitoring and food choices. 
    Journal of Diabetes Science and Technology. 2025
  • A randomized controlled trial using continuous glucose monitoring to guide food choices and diabetes self-care in people with type 2 diabetes not taking insulin. 
    Diabetes Technology & Therapeutics. 2025
  • AGP reports for glucose and insulin devices qualitative study: what patients and clinicians want. 
    Sci Diabetes Self Manag Care. 2025
  • Automated basal insulin delivery versus multiple daily injections in type 1 diabetes: results from a randomized parallel controlled trial. 
    Frontiers in Endocrinology. 2025
  • Automated insulin delivery in adults with type 2 diabetes: a nonrandomized clinical trial. 
    JAMA network open. 2025
  • Cardiovascular autonomic neuropathy defined by indices of heart rate variability is associated with cardiovascular disease: a longitudinal cohort study of participants with type 1 diabetes. 
    Cardiovascular Diabetology. 2025
  • Clinical and demographic characteristics associated with diabetes remission in six integrated health care systems: a retrospective cohort study. 
    Diabetes care. 2025
  • Continuous glucose monitoring. 
    JAMA. 2025
  • Continuous glucose monitoring (CGM) as a behavior modification tool: a case series on CGM-guided nutrition in people with type 2 diabetes not using insulin. 
    Clinical Diabetes. 2025
  • Continuous glucose monitoring data analysis 2.0: functional data pattern recognition and artificial intelligence applications. 
    Journal of Diabetes Science and Technology. 2025
  • Continuous glucose monitoring frequency and glycemic control in people with type 2 diabetes. 
    JAMA network open. 2025
  • Continuous glucose monitoring versus fasting blood glucose basal insulin titration: a retrospective analysis. 
    Diabetes & Metabolic Syndrome. 2025
  • Continuous glucose monitoring-based titration of once-weekly insulin icodec in insulin-naive individuals with type 2 diabetes (onwards 9): a phase 3b, multicenter, single-arm, treat-to-target clinical trial. 
    Diabetes Technology & Therapeutics. 2025
  • Continuous glucose monitoring-measured glucose levels during oral glucose tolerance testing in pregnancy. 
    Diabetes Technology & Therapeutics. 2025
  • Differential associations of somatic and cognitive-affective symptoms of depression with inflammation and insulin resistance: cross-sectional and longitudinal results from the Emotional Distress Sub-Study of the GRADE study. 
    Diabetologia. 2025
  • Differential treatment effects on beta-cell function using model-based parameters in type 2 diabetes: results from the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). 
    Diabetes care. 2025
  • Effects of continuous glucose monitoring discontinuation in adults with type 2 diabetes not using insulin. 
    Journal of Diabetes Science and Technology. 2025
  • Effects of continuous glucose monitoring versus blood glucose monitoring during a carbohydrate-restricted nutrition intervention in people with type 2 diabetes: 6-month follow-up outcomes from a randomized clinical trial. 
    Endocrine Practice. 2025
  • Glucose-lowering medication classes and cardiovascular outcomes in patients with type 2 diabetes. 
    JAMA network open. 2025
  • Glucose-lowering medications, glycemia, and cognitive outcomes: the GRADE Randomized Clinical Trial. 
    JAMA internal medicine. 2025
  • Glycaemic outcomes in adults with type 2 diabetes over 34 weeks with the Omnipod® 5 Automated Insulin Delivery System. 
    Diabetes, Obesity & Metabolism. 2025
  • Impact of continuous glucose monitoring versus blood glucose monitoring to support a carbohydrate-restricted nutrition intervention in people with type 2 diabetes. 
    Diabetes Technology & Therapeutics. 2025
  • Limitations in achieving glycemic targets from CGM data and persistence of severe hypoglycemia in adults with type 1 diabetes regardless of insulin delivery method. 
    Diabetes care. 2025
  • Monitoring ketonemia in people with diabetes: preliminary findings from real-world studies. 
    Diabetes Technology & Therapeutics. 2025
  • Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial. 
    Lancet (London, England). 2025
  • Patient-reported outcomes improve with a virtual diabetes care model that includes continuous glucose monitoring. 
    Telemedicine Journal and e-Health. 2025
  • Prevalence of diabetes among U.S. refugees and opportunities to improve screening, 2012-2022. 
    Journal of immigrant and minority health. 2025
  • Rapid improvements in glycemic management with use of continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin: 3-month analysis of the MOBILE study. 
    BMJ open diabetes research & care. 2025
  • Retrospective analysis of impact of automated insulin delivery technology on acute care utilisation from 2019 to 2021. 
    Diabetic Medicine. 2025
  • Safety and effectiveness of MiniMed™ 780G advanced hybrid closed-loop insulin intensification in adults with insulin-requiring type 2 diabetes. 
    Diabetes Technology & Therapeutics. 2025
  • The role of ultra-rapid-acting insulin analogs in diabetes: an expert consensus. 
    Journal of Diabetes Science and Technology. 2025
  • Weight gain was associated with worsening glycemia and cardiovascular and kidney outcomes in patients with type 2 diabetes independent of diabetes medication in the GRADE randomized controlled trial. 
    Diabetes care. 2025
  • A comparison of continuous glucose monitoring-measured time-in-range 70-180 mg/dL versus time-in-tight-range 70-140 mg/dL. 
    Diabetes Technology & Therapeutics. 2024
  • A scalable application of artificial intelligence-driven insulin titration program to transform type 2 diabetes management. 
    Diabetes Technology & Therapeutics. 2024
  • Continuous glucose monitoring metrics and hemoglobin A1c relationship in patients with type 2 diabetes treated by hemodialysis. 
    Diabetes Technology & Therapeutics. 2024
  • Continuous glucose monitoring prediction of gestational diabetes mellitus and perinatal complications. 
    Diabetes Technology & Therapeutics. 2024
  • Continuous glucose monitoring profiles in pregnancies with and without gestational diabetes mellitus. 
    Diabetes care. 2024
  • Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1. 
    The lancet. Diabetes & endocrinology. 2024
  • Continuous glucose monitoring-derived differences in pregnancies with and without adverse perinatal outcomes. 
    Obstetrics and Gynecology. 2024
  • Control-IQ technology use in individuals with high insulin requirements: results from the Multicenter Higher-IQ Trial. 
    Journal of Diabetes Science and Technology. 2024
  • Expert panel recommendations for a standardized ambulatory glucose profile report for connected insulin pens. 
    Diabetes Technology & Therapeutics. 2024
  • Frequency and severity of hypoglycemia under conditions of increased hypoglycemic risk with insulin efsitora alfa versus insulin glargine treatment in participants with type 2 diabetes. 
    Diabetes Therapy. 2024
  • Glucose levels measured with continuous glucose monitoring in uncomplicated pregnancies. 
    BMJ open diabetes research & care. 2024
  • Glycemia reduction in type 2 diabetes-hypoglycemia outcomes: a randomized clinical trial. 
    PloS One. 2024
  • Glycemic outcomes persist for up to 2 years in very young children with the Omnipod(®) 5 Automated Insulin Delivery System. 
    Diabetes Technology & Therapeutics. 2024
  • Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real-world analysis. 
    Diabetes, Obesity & Metabolism. 2024
  • Impact of insulin sensitivity and B-cell function over time on glycemic outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): differential treatment effects of dual therapy. 
    Diabetes care. 2024
  • Increase access, reduce disparities: recommendations for modifying medicaid CGM coverage eligibility criteria. 
    Journal of Diabetes Science and Technology. 2024
  • Long-term improvements in glycemic control with dexcom CGM use in adults with noninsulin-treated type 2 diabetes. 
    Diabetes Technology & Therapeutics. 2024
  • Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial. 
    Lancet (London, England). 2024
  • Psychosocial outcomes with the Omnipod® 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes. 
    Diabetes, Obesity & Metabolism. 2024
  • Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. 
    Lancet Reg Health Am. 2024
  • Severe hypoglycemia and impaired awareness of hypoglycemia persist in people with type 1 diabetes despite use of diabetes technology: results from a cross-sectional survey. 
    Diabetes care. 2024
  • The Diabetes Technology Society error grid and trend accuracy matrix for glucose monitors. 
    Journal of Diabetes Science and Technology. 2024
  • The use of rescue insulin in the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). 
    Diabetes care. 2024
  • Time in range, time in tight range, and average glucose relationships are modulated by glycemic variability: identification of a glucose distribution model connecting glycemic parameters using real-world data. 
    Diabetes Technology & Therapeutics. 2024
  • Two years with a tubeless automated insulin delivery system: a single-arm multicenter trial in children, adolescents, and adults with Type 1 diabetes. 
    Diabetes Technology & Therapeutics. 2024
  • Unleashing the potential of blood glucose monitoring data with the Ambulatory Glucose Profile Report. 
    Clinical Diabetes. 2024
  • A comparison of continuous glucose monitoring estimated hemoglobin A1c in adults with type 1 or type 2 diabetes. 
    Diabetes Technology & Therapeutics. 2023
  • A roadmap to an equitable digital diabetes ecosystem. 
    Endocrine Practice. 2023
  • Advancing diabetes quality measurement in the era of continuous glucose monitoring. 
    Sci Diabetes Self Manag Care. 2023
  • Assessing time in range with postprandial glucose-focused titration of ultra rapid lispro (URLi) in people with type 1 diabetes. 
    Diabetes Therapy. 2023
  • Assessment of the glucose management indicator using different sampling durations. 
    Diabetes Technology & Therapeutics. 2023
  • BMI, insulin sensitivity, and cognition in early type 2 diabetes: The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study. 
    Obesity (Silver Spring, Md.). 2023
  • CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes. 
    Cardiovascular Diabetology. 2023
  • Comprehensive telehealth model to support diabetes self-management. 
    JAMA network open. 2023
  • Consensus recommendations for the use of automated insulin delivery technologies in clinical practice. 
    Endocrine Reviews. 2023
  • Continuous glucose monitoring provides durable glycemic benefit in adolescents and young adults with type 1 diabetes: 12-month follow-up results. 
    Pediatric Diabetes. 2023
  • Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: the head-to-head randomized controlled InRange trial. 
    Diabetes, Obesity & Metabolism. 2023
  • Correlation between time in range and HbA1c in people with type 2 diabetes on basal insulin: post hoc analysis of the SWITCH PRO study. 
    Diabetes Therapy. 2023
  • Discordance between glucose management indicator and glycated hemoglobin in people without diabetes. 
    Diabetes Technology & Therapeutics. 2023
  • Impact of severe hypoglycaemia requiring hospitalization on mortality in people with type 1 diabetes: a national retrospective observational cohort study. 
    Diabetes, Obesity & Metabolism. 2023
  • Improved glycemia with hybrid closed-loop versus continuous subcutaneous insulin infusion therapy: results from a randomized controlled trial. 
    Diabetes Technology & Therapeutics. 2023
  • Increased derived time in range is associated with reduced risk of major adverse cardiovascular events, severe hypoglycemia, and microvascular events in type 2 diabetes: a post hoc analysis of DEVOTE. 
    Diabetes Technology & Therapeutics. 2023
  • Psychosocial outcomes with the Omnipod® 5 automated insulin delivery system in children and adolescents with type 1 diabetes and their caregivers. 
    Pediatric Diabetes. 2023
  • Roadmap to the effective use of continuous glucose monitoring in primary care. 
    Diabetes Spectrum. 2023
  • Roadmap to the effective use of continuous glucose monitoring: innovation, investigation, and implementation. 
    Diabetes Spectrum. 2023
  • Roadmaps to continuous glucose monitoring's role in transforming diabetes management. 
    Diabetes Spectrum. 2023
  • Safety and efficacy of the Omnipod 5 Automated Insulin Delivery System in adults with type 2 diabetes: from injections to hybrid closed-loop therapy. 
    Diabetes care. 2023
  • Safety and glycemic outcomes during the MiniMed(TM) advanced hybrid closed-loop system pivotal trial in children and adolescents with type 1 diabetes. 
    Diabetes Technology & Therapeutics. 2023
  • The relationship between percent time <70 mg/dL and percent time <54 mg/dL measured by continuous glucose monitoring. 
    Diabetes Technology & Therapeutics. 2023
  • A comparison of postprandial glucose control in the Medtronic advanced hybrid closed-loop system versus 670G. 
    Diabetes Technology & Therapeutics. 2022
  • A safe and simple algorithm for adding and adjusting mealtime insulin to basal-only therapy. 
    Clinical Diabetes. 2022
  • Benefit of continuous glucose monitoring in reducing hypoglycemia is sustained through 12 months of use among older adults with type 1 diabetes. 
    Diabetes Technology & Therapeutics. 2022
  • Can faster aspart be used to optimize glycemic control with insulin pump therapy? From expectations to lessons learned after a year of use in the United States. 
    Clinical Diabetes. 2022
  • Comparing patch vs pen bolus insulin delivery in type 2 diabetes using continuous glucose monitoring metrics and profiles. 
    Journal of Diabetes Science and Technology. 2022
  • Continuous glucose monitoring in adults with type 1 diabetes with 35 years duration from the DCCT/EDIC Study. 
    Diabetes care. 2022
  • Continuous ketone monitoring consensus report 2021. 
    Journal of Diabetes Science and Technology. 2022
  • Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. 
    The lancet. Diabetes & endocrinology. 2022
  • How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: findings from the first investigation with the Omnipod® 5 System. 
    Diabetes Research and Clinical Practice. 2022
  • How use of continuous glucose monitoring can address therapeutic inertia in primary care. 
    Postgraduate Medicine. 2022
  • Impact of temporary glycemic target use in the hybrid and advanced hybrid closed-loop systems. 
    Diabetes Technology & Therapeutics. 2022
  • Interindividual variability in average glucose-glycated haemoglobin relationship in type 1 diabetes and implications for clinical practice. 
    Diabetes, Obesity & Metabolism. 2022
  • Randomized comparison of self-monitored blood glucose (BGM) versus continuous glucose monitoring (CGM) data to optimize glucose control in type 2 diabetes. 
    Journal of Diabetes and Its Complications. 2022
  • Real-world evidence supporting Tandem Control-IQ Hybrid Closed-Loop success in the Medicare and Medicaid type 1 and type 2 diabetes populations. 
    Diabetes Technology & Therapeutics. 2022
  • Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. 
    Cardiovascular Diabetology. 2022
  • Safety and glycemic outcomes during the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in adolescents and adults with type 1 diabetes. 
    Diabetes Technology & Therapeutics. 2022
  • Safety and glycemic outcomes with a tubeless automated insulin delivery system in very young children with type 1 diabetes: a single-arm multicenter clinical trial. 
    Diabetes care. 2022
  • Symptomatic diabetic autonomic neuropathy in type 1 diabetes (T1D): findings from the T1D exchange. 
    Journal of Diabetes and Its Complications. 2022
  • The optimal duration of a run-in period to initiate continuous glucose monitoring for a randomized trial. 
    Diabetes Technology & Therapeutics. 2022
  • A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. 
    Lancet (London, England). 2021
  • Acacia gum is well tolerated while increasing satiety and lowering peak blood glucose response in healthy human subjects. 
    Nutrients. 2021
  • Addressing shortfalls of laboratory HbA(1c) using a model that incorporates red cell lifespan. 
    eLife. 2021
  • Beyond A1C-standardization of continuous glucose monitoring reporting: why it is needed and how it continues to evolve. 
    Diabetes Spectrum. 2021
  • Continuous glucose monitoring integration for remote diabetes management: virtual diabetes care with case studies. 
    Diabetes Technology & Therapeutics. 2021
  • Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. 
    JAMA. 2021
  • Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia. 
    Diabetes, Obesity & Metabolism. 2021
  • Effect of professional CGM (pCGM) on glucose management in type 2 diabetes patients in primary care. 
    Journal of Diabetes Science and Technology. 2021
  • First outpatient evaluation of a tubeless automated insulin delivery system with customizable glucose targets in children and adults with type 1 diabetes. 
    Diabetes Technology & Therapeutics. 2021
  • Flash CGM is associated with reduced diabetes events and hospitalizations in insulin-treated type 2 diabetes. 
    Journal of the Endocrine Society. 2021
  • Glycaemic profiles of diverse patients with type 2 diabetes using basal insulin: MOBILE study baseline data. 
    Diabetes, Obesity & Metabolism. 2021
  • Hypoglycemia and glycemic control in older adults with type 1 diabetes: baseline results from the WISDM Study. 
    Journal of Diabetes Science and Technology. 2021
  • Improved glycemic control in 3,592 adults with type 2 diabetes mellitus initiating a tubeless insulin management system. 
    Diabetes Research and Clinical Practice. 2021
  • Initiating insulin in the emergency center and urgent care to prevent hospital admission for patients with hyperglycemia: a unique insulin starter kit. 
    Journal of Diabetes Science and Technology. 2021
  • Lived experience of advanced hybrid closed-loop versus hybrid closed-loop: patient-reported outcomes and perspectives. 
    Diabetes Technology & Therapeutics. 2021
  • Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies. 
    Diabetes, Obesity & Metabolism. 2021
  • Lost in translation: a disconnect between the science and Medicare coverage criteria for continuous subcutaneous insulin infusion. 
    Diabetes Technology & Therapeutics. 2021
  • Making sense of glucose metrics in diabetes: linkage between postprandial glucose (PPG), time in range (TIR) & hemoglobin A1c (A1C). 
    Postgraduate Medicine. 2021
  • Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. 
    Diabetes care. 2021
  • Real-world, patient-reported and clinic data from individuals with type 1 diabetes using the MiniMed 670G hybrid closed-loop system. 
    Diabetes Technology & Therapeutics. 2021
  • Remote application and use of real-time continuous glucose monitoring by adults with type 2 diabetes in a virtual diabetes clinic. 
    Diabetes Technology & Therapeutics. 2021
  • Renal complications and duration of diabetes: an international comparison in persons with type 1 diabetes. 
    Diabetes Therapy. 2021
  • Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. 
    Diabetes care. 2021
  • The digital/virtual diabetes clinic: the future Is now-recommendations from an international panel on diabetes digital technologies introduction. 
    Diabetes Technology & Therapeutics. 2021
  • The effect of discontinuing continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin. 
    Diabetes care. 2021
  • Trial of a new diabetes education model: closing the gap in health disparity for people with diabetes. 
    Journal of Diabetes Science and Technology. 2021
  • Ultrarapid lispro demonstrates similar time in target range to lispro with a hybrid closed-loop system. 
    Diabetes Technology & Therapeutics. 2021
  • Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. 
    Diabetologia. 2020
  • Diabetes telehealth solutions: improving self-management through remote initiation of continuous glucose monitoring. 
    Journal of the Endocrine Society. 2020
  • Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: a randomized clinical trial. 
    JAMA. 2020
  • Effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes: a randomized clinical trial. 
    JAMA. 2020
  • Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA). 
    Pediatric Diabetes. 2020
  • Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA). 
    Diabetologia. 2020
  • InRange: comparison of the second-generation basal insulin analogues glargine 300 U/mL and degludec 100 U/mL in persons with type 1 diabetes using continuous glucose monitoring-study design. 
    Diabetes Therapy. 2020
  • International Diabetes Center: COVID-19 won't stop us from fulfilling our mission. 
    Journal of Diabetes Science and Technology. 2020
  • Ultra-rapid lispro improves postprandial glucose control and time in range in type 1 diabetes compared to lispro: PRONTO-T1D Continuous Glucose Monitoring Substudy. 
    Diabetes Technology & Therapeutics. 2020
  • Use of a diabetes-specific nutritional shake to replace a daily breakfast and afternoon snack improves glycemic responses assessed by continuous glucose monitoring in people with type 2 diabetes: a randomized clinical pilot study. 
    BMJ open diabetes research & care. 2020
  • . 2018;41:2275-2280. 
    Diabetes care. 2019
  • Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial. 
    Lancet (London, England). 2019
  • Continuous glucose monitoring profiles in healthy nondiabetic participants: a multicenter prospective study. 
    Journal of Clinical Endocrinology and Metabolism. 2019
  • Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: a multicentre, randomized controlled trial using continuous glucose monitoring. 
    Diabetes, Obesity & Metabolism. 2019
  • Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME(R) trial. 
    Age and Ageing. 2019
  • Emphasizing optimal diabetes management for all races/ethnicities, but not race/ethnicity-specific cut points for hemoglobin A1c. 
    JAMA ophthalmology. 2019
  • Evaluation of insulin glargine and exenatide alone and in combination: a randomized clinical trial with continuous glucose monitoring and ambulatory glucose profile analysis. 
    Endocrine Practice. 2019
  • Impact of diabetes and hyperglycemia on health care utilization, infection risk, and survival in patients with cancer receiving glucocorticoids with chemotherapy. 
    Journal of Diabetes and Its Complications. 2019
  • Implementation of basal-bolus therapy in type 2 diabetes: a randomized controlled trial comparing bolus insulin delivery using an insulin patch with an insulin pen. 
    Diabetes Technology & Therapeutics. 2019
  • Insulin dosing guidance to optimise type 2 diabetes management - authors' reply. 
    Lancet (London, England). 2019
  • Rationale and design for a GRADE substudy of continuous glucose monitoring. 
    Diabetes Technology & Therapeutics. 2019
  • State of type 1 diabetes management and outcomes from the T1D Exchange in 2016-2018. 
    Diabetes Technology & Therapeutics. 2019
  • The association of biochemical hypoglycemia with the subsequent risk of a severe hypoglycemic event: analysis of the DCCT data set. 
    Diabetes Technology & Therapeutics. 2019
  • The relationships between time in range, hyperglycemia metrics, and HbA1c. 
    Journal of Diabetes Science and Technology. 2019
  • Validation of time in range as an outcome measure for diabetes clinical trials. 
    Diabetes care. 2019
  • Young children have higher variability of insulin requirements: observations during hybrid closed-loop insulin delivery. 
    Diabetes care. 2019
  • Alogliptin in patients with type 2 diabetes receiving metformin and sulfonylurea therapies in the EXAMINE Trial. 
    American Journal of Medicine. 2018
  • Average clinician-measured blood pressures and cardiovascular outcomes in patients with type 2 diabetes mellitus and ischemic heart disease in the EXAMINE Trial. 
    Journal of the American Heart Association. 2018
  • Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. 
    Lancet (London, England). 2018
  • Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: efficacy and safety from a randomized double-blind trial. 
    Diabetes, Obesity & Metabolism. 2018
  • Glucose Management Indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. 
    Diabetes care. 2018
  • Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4). 
    Diabetes, Obesity & Metabolism. 2018
  • High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. 
    Diabetes, Obesity & Metabolism. 2018
  • Optimal sampling duration for continuous glucose monitoring to determine long-term glycemic control. 
    Diabetes Technology & Therapeutics. 2018
  • Time savings using a standardized glucose reporting system and ambulatory glucose profile. 
    Journal of Diabetes Science and Technology. 2018
  • Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome. 
    Clinical Cardiology. 2018
  • 2017;40:777-83. 
    Diabetes care. 2017
  • Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol. 
    BMJ open. 2017
  • Association of glycemic variability in type 1 diabetes with progression of microvascular outcomes in the Diabetes Control and Complications Trial. 
    Diabetes care. 2017
  • Comparison of insulin glargine 300 units/mL and 100 units/mL in adults with type 1 diabetes: continuous glucose monitoring profiles and variability using morning or evening injections. 
    Diabetes care. 2017
  • Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. 
    Diabetes, Obesity & Metabolism. 2017
  • Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. 
    Annals of Internal Medicine. 2017
  • Digital health care by in silico glycation of HbA1 blood cells. 
    Journal of Diabetes Science and Technology. 2017
  • Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: an analysis using continuous glucose monitoring. 
    Diabetes/Metabolism Research and Reviews. 2017
  • Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND Randomized Clinical Trial. 
    JAMA. 2017
  • Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. 
    The lancet. Diabetes & endocrinology. 2017
  • Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). 
    Diabetes care. 2017
  • Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. 
    Diabetes Technology & Therapeutics. 2017
  • Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naive people with type 2 diabetes: 12-month results from the EDITION 3 trial. 
    Diabetes and Metabolism. 2017
  • Identifying trends in undiagnosed diabetes in U.S. adults by using a confirmatory definition: a cross-sectional study. 
    Annals of Internal Medicine. 2017
  • Liraglutide and renal outcomes in type 2 diabetes. 
    New England Journal of Medicine. 2017
  • REPLACE-BG: A randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. 
    Diabetes care. 2017
  • Racial differences in the relationship of glucose concentrations and hemoglobin A1c levels. 
    Annals of Internal Medicine. 2017
  • Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: the EXAMINE trial. 
    Diabetes, Obesity & Metabolism. 2017
  • The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading. 
    Diabetes care. 2017
  • The hybrid closed loop therapy system: a step closer to an artificial pancreas. 
    Minn Physician. 2017
  • Angiotensin-converting enzyme inhibitor use and major cardiovascular outcomes in type 2 diabetes mellitus treated with the dipeptidyl peptidase 4 inhibitor alogliptin. 
    Hypertension (Dallas, Tex.. 2016
  • Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE Trial. 
    Diabetes care. 2016
  • Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: The LixiLan-L randomized trial. 
    Diabetes care. 2016
  • Efficacy and safety of flexible versus fixed dosing intervals of insulin glargine 300 U/mL in people with type 2 diabetes. 
    Diabetes Technology & Therapeutics. 2016
  • Hospital insulin protocol aims for glucose control in glucocorticoid-induced hyperglycemia. 
    Endocrine Practice. 2016
  • Hypoglycemia in older adults with type 1 diabetes. 
    Diabetes Technology & Therapeutics. 2016
  • Liraglutide and cardiovascular outcomes in type 2 diabetes. 
    New England Journal of Medicine. 2016
  • Racial differences in and prognostic value of biomarkers of hyperglycemia. 
    Diabetes care. 2016
  • Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3. 
    Diabetes, Obesity & Metabolism. 2016
  • Recurrent endocrine cycles. 
    Journal of Diabetes Science and Technology. 2016
  • Reduction in short-acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes. 
    Journal of Diabetes. 2016
  • Risk factors associated with severe hypoglycemia in older adults with type 1 diabetes. 
    Diabetes care. 2016
  • Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. 
    JAMA. 2016
  • The effect of treatment of obstructive sleep apnea on glycemic control in type 2 diabetes. 
    American Journal of Respiratory and Critical Care Medicine. 2016
  • Clinical utility of SMBG: recommendations on the use and reporting of SMBG in clinical research. 
    Diabetes care. 2015
  • Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange Clinic registry. 
    Diabetes care. 2015
  • Design of FLAT-SUGAR: randomized trial of prandial insulin versus prandial GLP-1 receptor agonist together with basal insulin and metformin for high-risk type 2 diabetes. 
    Diabetes care. 2015
  • Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes Randomized Clinical Trial. 
    JAMA. 2015
  • Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension. 
    Diabetes, Obesity & Metabolism. 2015
  • Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers!. 
    Diabetes care. 2015
  • Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort study. 
    BMJ open diabetes research & care. 2015
  • Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. 
    Diabetologia. 2015
  • Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting, and research needs: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. 
    Diabetes care. 2015
  • LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations. 
    Diabetes, Obesity & Metabolism. 2015
  • Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. 
    Diabetologia. 2015
  • Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. 
    Diabetes care. 2015
  • Multicenter observational study of the first-generation intravenous blood glucose monitoring system in hospitalized patients. 
    Journal of Diabetes Science and Technology. 2015
  • New insulin Glargine 300 Units/mL versus Glargine 100 Units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). 
    Diabetes care. 2015
  • New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). 
    Diabetes, Obesity & Metabolism. 2015
  • Obesity in youth with type 1 diabetes in Germany, Austria, and the United States. 
    Journal of Pediatrics. 2015
  • Predictors of hypoglycemia in the ASPIRE In-Home study and effects of automatic suspension of insulin delivery. 
    Journal of Diabetes Science and Technology. 2015
  • Response to comment on Wong et al. Real-time continuous glucose monitoring among participants in the T1D exchange clinic registry. 
    Diabetes care. 2015
  • Safety and efficacy of insulin therapy delivered via a 4mm pen needle in obese patients with diabetes. 
    Mayo Clinic Proceedings. 2015
  • Sensor-augmented pump and multiple daily injection therapy in the United States and Canada: post-hoc analysis of a randomized controlled trial. 
    Canadian journal of diabetes. 2015
  • A patient-level analysis of efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine added to oral antidiabetes agents in people with type 2 diabetes
    2014
  • Application of PK/PD modeling and simulation to dosing regimen optimization of high-dose human regular U-500 insulin. 
    Journal of Diabetes Science and Technology. 2014
  • Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM. 
    Diabetes, Obesity & Metabolism. 2014
  • Depression in adults in the T1D Exchange Clinic Registry. 
    Diabetes care. 2014
  • Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial. 
    Diabetologia. 2014
  • LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial. 
    Pancreas. 2014
  • Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine. 
    Diabetes care. 2014
  • New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). 
    Diabetes care. 2014
  • Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry. 
    Diabetes care. 2014
  • ASPIRE In-Home: rationale, design, and methods of a study to evaluate the safety and efficacy of automatic insulin suspension for nocturnal hypoglycemia. 
    Journal of Diabetes Science and Technology. 2013
  • Alogliptin after acute coronary syndrome in patients with type 2 diabetes. 
    New England Journal of Medicine. 2013
  • Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. 
    Diabetes care. 2013
  • Challenges and future directions of the T1D Exchange Clinic Network and registry. 
    Journal of Diabetes Science and Technology. 2013
  • Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. 
    American Heart Journal. 2013
  • Determining the influence of type 1 diabetes on two common eating disorder questionnaires. 
    Diabetes Educator. 2013
  • Differences in the management of type 1 diabetes among adults under excellent control compared with those under poor control in the T1D Exchange Clinic Registry. 
    Diabetes care. 2013
  • Diurnal glucose profiles using continuous glucose monitoring to identify the glucose-lowering characteristics of colesevelam HCl (Welchol). 
    Endocrine Practice. 2013
  • Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. 
    Diabetes care. 2013
  • Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks. 
    Diabetes, Obesity & Metabolism. 2013
  • Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. 
    Diabetes care. 2013
  • No racial differences in the association of glycated hemoglobin with kidney disease and cardiovascular outcomes. 
    Diabetes care. 2013
  • Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). 
    Diabetes Technology & Therapeutics. 2013
  • Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile. 
    Journal of Diabetes Science and Technology. 2013
  • Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. 
    Journal of Clinical Endocrinology and Metabolism. 2013
  • Threshold-based insulin-pump interruption for reduction of hypoglycemia. 
    New England Journal of Medicine. 2013
  • A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. 
    Diabetes care. 2012
  • Advanced meter features improve postprandial and paired self-monitoring of blood glucose in individuals with diabetes: results of the Actions with the CONTOUR Blood Glucose Meter and Behaviors in Frequent Testers (ACT) study. 
    Diabetes Technology & Therapeutics. 2012
  • Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. 
    Diabetes care. 2012
  • Can a tool that automates insulin titration be a key to diabetes management?. 
    Diabetes Technology & Therapeutics. 2012
  • Characteristics of persons with an eating disorder and type 1 diabetes and psychological comparisons with persons with an eating disorder and no diabetes. 
    International Journal of Eating Disorders. 2012
  • Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. 
    Pediatric Diabetes. 2012
  • Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. 
    Cardiovascular Diabetology. 2012
  • Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial). 
    Diabetes Therapy. 2012
  • Health-related quality of life and treatment satisfaction in the Sensor-Augmented Pump Therapy for A1C Reduction 3 (STAR 3) trial. 
    Diabetes Technology & Therapeutics. 2012
  • Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 
    Diabetologia. 2012
  • Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting. 
    Diabetes, Obesity & Metabolism. 2012
  • Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. 
    Diabetes care. 2012
  • Preadmission glycemic control and changes to diabetes mellitus treatment regimen after hospitalization. 
    Endocrine Practice. 2012
  • The T1D Exchange clinic registry. 
    Journal of Clinical Endocrinology and Metabolism. 2012
  • Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience. 
    Diabetes Technology & Therapeutics. 2011
  • Comparison of a novel insulin bolus-patch with pen/syringe injection to deliver mealtime insulin for efficacy, preference, and quality of life in adults with diabetes: a randomized, crossover, multicenter study. 
    Diabetes Technology & Therapeutics. 2011
  • DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. 
    Diabetic Medicine. 2011
  • EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. 
    American Heart Journal. 2011
  • Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting. 
    Current Medical Research and Opinion. 2011
  • Exenatide BID observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting. 
    Current Medical Research and Opinion. 2011
  • Feasibility of measuring gastric emptying time, with a wireless motility device, after subjects consume fiber-matched liquid and solid breakfasts. 
    Appetite. 2011
  • Improving blood pressure control in individuals with diabetes: a quality improvement collaborative. 
    Joint Commission journal on quality and patient safety. 2011
  • Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. 
    Diabetologia. 2011
  • Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. 
    Archives of Internal Medicine. 2011
  • Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. 
    Diabetes care. 2011
  • The Minnesota Diabetes Plan 2015: stemming the tide on an epidemic and improving patient care. 
    Minnesota Medicine. 2011
  • Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. 
    Annals of Internal Medicine. 2011
  • Diabetes and cancer: a consensus report. 
    CA: A Cancer Journal for Clinicians. 2010
  • Diabetes and cancer: a consensus report. 
    Diabetes care. 2010
  • Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. 
    New England Journal of Medicine. 2010
  • Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. 
    American Journal of Medicine. 2010
  • Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. 
    Lancet (London, England). 2010
  • Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. 
    Diabetes care. 2010
  • Point: The reporting of estimated glucose with hemoglobin A1c. 
    Clinical Chemistry. 2010
  • The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. 
    BMJ (Clinical research ed.). 2010
  • The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. 
    BMJ (Clinical research ed.). 2010
  • A1C predicts type 2 diabetes and impaired glucose tolerance in a population at risk: the community diabetes prevention project. 
    Diabetology & Metabolic Syndrome. 2009
  • Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. 
    Diabetes, Obesity & Metabolism. 2009
  • Detection of hypoglycemia with continuous interstitial and traditional blood glucose monitoring using the FreeStyle Navigator Continuous Glucose Monitoring System. 
    Diabetes Technology & Therapeutics. 2009
  • Diurnal glucose patterns of exenatide once weekly: a 1-year study using continuous glucose monitoring with ambulatory glucose profile analysis. 
    Endocrine Practice. 2009
  • Does availability of AIR insulin increase insulin use and improve glycemic control in patients with type 2 diabetes?. 
    Diabetes Technology & Therapeutics. 2009
  • Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. 
    Current Medical Research and Opinion. 2009
  • Low cardiorespiratory fitness in people at risk for type 2 diabetes: early marker for insulin resistance. 
    Diabetology & Metabolic Syndrome. 2009
  • Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. 
    Diabetes care. 2008
  • Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. 
    Diabetes Technology & Therapeutics. 2008
  • Consensus report of the coalition for clinical research-self-monitoring of blood glucose. 
    Journal of Diabetes Science and Technology. 2008
  • Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. 
    Current Medical Research and Opinion. 2008
  • Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents. 
    Diabetes care. 2008
  • Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. 
    American Journal of Cardiology. 2007
  • Treatment models from the International Diabetes Center: advancing from oral agents to insulin therapy in type 2 diabetes. 
    Endocrine Practice. 2006
  • Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. 
    Diabetes care. 2005
  • Impact of modem-transferred blood glucose data on clinician work efficiency and patient glycemic control. 
    Diabetes Technology & Therapeutics. 2005
  • Macrovascular risk factors in patients with diabetes: physician treatment strategies and extent of control. 
    Endocrine Practice. 2005
  • Undetected, uncontrolled blood pressure in type 2 diabetes: self-monitored blood pressure profiles. 
    Blood Pressure. 2004
  • Characterizing blood pressure control in individuals with Type 2 diabetes: the relationship between clinic and self-monitored blood pressure. 
    Diabetic Medicine. 2003
  • Clinical impact of prandial state, exercise, and site preparation on the equivalence of alternative-site blood glucose testing. 
    Diabetes care. 2003
  • Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. 
    JAMA. 2003
  • Use of an automated device for alternative site blood glucose monitoring. 
    Diabetes care. 2001
  • A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. 
    Diabetes care. 2000
  • Identifying variables associated with inaccurate self-monitoring of blood glucose: proposed guidelines to improve accuracy. 
    Diabetes Educator. 2000
  • Optimization of insulin therapy in patients with type 2 diabetes. 
    Endocrine Practice. 2000
  • Cost-effectiveness of medical nutrition therapy provided by dietitians for persons with non-insulin-dependent diabetes mellitus. 
    Journal of the American Dietetic Association. 1995
  • Effectiveness of medical nutrition therapy provided by dietitians in the management of non-insulin-dependent diabetes mellitus: a randomized, controlled clinical trial. 
    Journal of the American Dietetic Association. 1995
  • A joint venture with the commonwealth of independent states. 
    Diabetes care. 1993
  • Practice guidelines for nutrition care by dietetics practitioners for outpatients with non-insulin-dependent diabetes mellitus: methodologies for field-testing and cost-effectiveness analysis. 
    Journal of the American Dietetic Association. 1992
  • Observations on C-peptide and free insulin in the blood during continuous subcutaneous insulin infusion and conventional insulin therapy. 
    Diabetes. 1985
  • Observations on blood lipid and intermediary metabolite concentrations during conventional insulin treatment or CSII. 
    Diabetes. 1985
  • Observations on control of glycemia with conventional insulin therapy or continuous subcutaneous insulin infusion. 
    Diabetes. 1985
    • Editorial Article
  • The Glucose Management Indicator: time to change course [editorial]?. 
    Diabetes care.  47. 2024
  • Continuous glucose monitoring for type 2 diabetes: how does it compare with type 1 diabetes [editorial]?. 
    Diabetes Technology & Therapeutics.  24. 2022
  • More green, less red: how color standardization may facilitate effective use of CGM data [editorial]. 
    Journal of Diabetes Science and Technology.  16. 2022
  • Continuous glucose monitoring and glycemic control in patients with type 2 diabetes treated with basal insulin [editorial]. 
    JAMA.  326. 2021
  • Glucose management for exercise using continuous glucose monitoring: should sex and prandial state be additional considerations [editorial]?. 
    Diabetologia.  64. 2021
  • Continuous glucose monitoring-derived data report-simply a better management tool [editorial]. 
    Diabetes care.  43. 2020
  • Duration of hybrid closed-loop insulin therapy to achieve representative glycemic outcomes in adults with type 1 diabetes [editorial]. 
    Diabetes care.  43. 2020
  • Glucose management indicator (GMI): insights and validation using Guardian 3 and Navigator 2 sensor data [editorial]. 
    Diabetes care.  42. 2019
  • Continuous glucose monitoring: transforming diabetes management step by step [editorial]. 
    Lancet (London, England).  391. 2018
  • Evaluating interventions and titrations using fasting blood glucose [editorial]. 
    Journal of Diabetes Science and Technology.  12. 2018
  • Identifying trends in undiagnosed diabetes in U.S. adults [editorial]. 
    Annals of Internal Medicine.  168. 2018
  • Racial differences in the relationship of glucose concentrations and hemoglobin A1c levels [editorial]. 
    Annals of Internal Medicine.  168. 2018
  • Continuous glucose monitoring in patients with type 1 diabetes using insulin injections [editorial]. 
    Diabetes care.  39. 2016
  • Trends in insulin use and diabetes control in the U.S.: 1988-1994 and 1999-2012 [editorial]. 
    Diabetes care.  39. 2016
  • Threshold insulin-pump interruption to reduce hypoglycemia [editorial]. 
    New England Journal of Medicine.  369. 2013
  • Integrated practice units are bridges, not 'archipelagoes' [editorial]. 
    Health Affairs.  27. 2008
  • The insulin sliding scale is not dead [editorial]. 
    Archives of Internal Medicine.  158. 1998
    • Conference Poster
  • Autonomic neuropathy in type 1 diabetes (T1D): findings from the T1D Exchange [poster]
    2019
  • Effect of professional CGM (pCGM) on glucose management in type 2 diabetes patients in primary care [poster]
    2019
  • Hybrid closed-loop in adults with type 1 diabetes: impact of baseline A1c on glucose outcomes and insulin delivery [poster]
    2019
  • Low level of agreement in evaluation of continuous glucose monitoring profiles [poster]
    2019
  • Optimal sampling duration of hybrid closed-loop therapy to determine long-term glycemic control in adults with type 1 diabetes [poster]
    2019
  • Comparing patch vs.pen bolus insulin delivery in type 2 diabetes using continuous glucose monitoring metrics and profiles [poster]
    2018
  • Efficacy and safety of faster aspart compared with insulin aspart both with insulin degludec in adults with T1D [poster]
    2018
  • Hypoglycaemia with mealtime fast-acting insulin aspart versis insulin aspart across two large type 1 diabetes trials [poster]
    2018
  • Impact of diabetes and hyperglycemia on health care utilization, infection risk, and survival in patients with cancer receiving glucocorticoids with chemotherapy [poster]
    2018
  • Improved glycemic control with carbohydrate counting for adjustment of fast-acting insulin aspart versus insulin aspart in subjects with type 1 diabetes [poster]
    2018
  • Incidence of diabetes and hyperglycemia among patients receiving glucocorticoids with chemotherapy [poster]
    2018
  • Increased HbA1c variability may shorten time to microalbuminuria development in type 1 diabetes (T1D) [poster]
    2018
  • Optimizing basal-bolus therapy in T2D—a randomized controlled trial comparing bolus insulin delivery using an insulin patch vs. an insulin pen [poster]
    2018
  • Real-world improvement in above-target estimated A1c with sequential use of professional flash continuous glucose monitoring for individuals with diabetes [poster]
    2018
  • Pivotal trial of a hybrid closed-loop system in type 1 diabetes (T1D) [poster]
    2016
  • Reducing staff time with optimized work flows and standardized ambulatory glucose profile (AGP) [poster]
    2015
    • Report
  • Diagnosis and managment of type 2 diabetes mellitus in adults [health care guideline]
    2009
  • Diagnosis and managment of type 2 diabetes mellitus in adults [health care guideline]
    2008
    • Review
  • Addressing the diabetes tsunami requires expanded access to diabetes technologies [review]. 
    Journal of Diabetes Science and Technology. 2026
  • Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an international consensus statement [review]. 
    The lancet. Diabetes & endocrinology. 2026
  • Challenges in and opportunities for individualising diabetes technology: a position statement by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group [review]. 
    Diabetologia. 2026
  • Challenges in and opportunities for individualizing diabetes technology: a position statement by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group [review]. 
    Diabetes care. 2026
  • Clinical impact of continuous glucose monitoring in noninsulin treated type 2 diabetes: a review [review]. 
    Diabetes Technology & Therapeutics. 2026
  • Continuous ketone monitoring for people with diabetes: international expert recommendations on the application of a new technology [review]. 
    The lancet. Diabetes & endocrinology. 2026
  • Primary care and diabetes technologies and treatments [review]. 
    Diabetes Technology & Therapeutics. 2026
  • Continuous glucose monitoring to guide lifestyle choices with a focus on nutrition in the management of type 2 diabetes: a systematic review and meta-analysis [review]. 
    Journal of Diabetes Science and Technology. 2025
  • Effective strategies for the prevention and mitigation of phosphatidylinositol-3-kinase inhibitor-associated hyperglycemia: optimizing patient care [review]. 
    Clinical Breast Cancer. 2025
  • Evolution of the artificial pancreas: components and integration-CGMs, insulin, and AP systems [review]. 
    Journal of Diabetes Science and Technology. 2025
  • Integrating continuous dual glucose-ketone monitoring into clinical practice [review]. 
    Diabetes Technology & Therapeutics. 2025
  • Primary care and diabetes technologies and treatments [review]. 
    Diabetes Technology & Therapeutics. 2025
  • Registration and real-life studies on automated insulin delivery systems [review]. 
    Diabetes Technology & Therapeutics. 2025
  • Registration and real-life studies on automated insulin delivery systems [review]. 
    Journal of Diabetes Science and Technology. 2025
  • The role of advanced technologies in improving diabetes outcomes [review]. 
    American Journal of Managed Care. 2025
  • The role, potential benefits and cost-effectiveness of digital tools for diabetes management [review]. 
    Clinical Therapeutics. 2025
  • Decreasing the burden of carbohydrate counting and meal announcement with automated insulin delivery, meal recognition, and autocorrection doses: a case study [review]. 
    Diabetes Technology & Therapeutics. 2024
  • Is it time to move beyond TIR to TITR? Real-world data from over 20,000 users of continuous glucose monitoring in patients with type 1 and type 2 diabetes [review]. 
    Diabetes Technology & Therapeutics. 2024
  • Once-weekly insulin efsitora alfa: design and rationale for the QWINT phase 3 clinical development programme [review]. 
    Diabetes, Obesity & Metabolism. 2024
  • Primary care and diabetes technologies and treatments [review]. 
    Diabetes Technology & Therapeutics. 2024
  • Update on measuring ketones [review]. 
    Journal of Diabetes Science and Technology. 2024
  • Use of continuous glucose monitoring when initiating glucagon-like peptide-1 receptor agonist therapy in insulin-treated diabetes [review]. 
    Diabetes, Obesity & Metabolism. 2024
  • Using continuous glucose monitoring data in daily clinical practice [review]. 
    Cleveland Clinic Journal of Medicine. 2024
  • Automated insulin delivery: benefits, challenges, and recommendations. A consensus report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association [review]. 
    Diabetologia. 2023
  • Biomarkers for the diagnosis of heart failure in people with diabetes: a consensus report from Diabetes Technology Society [review]. 
    Progress in Cardiovascular Diseases. 2023
  • Continuous glucose monitoring and metrics for clinical trials: an international consensus statement [review]. 
    The lancet. Diabetes & endocrinology. 2023
  • Coverage for continuous glucose monitoring for individuals with type 2 diabetes treated with nonintensive therapies: an evidence-based approach to policymaking [review]. 
    Diabetes Technology & Therapeutics. 2023
  • Personalized glycated hemoglobin in diabetes management: closing the gap with glucose management indicator [review]. 
    Diabetes Technology & Therapeutics. 2023
  • Prevalence, cost, and burden of diabetic ketoacidosis [review]. 
    Diabetes Technology & Therapeutics. 2023
  • Primary care and diabetes technologies and treatments [review]. 
    Diabetes Technology & Therapeutics. 2023
  • Automated insulin delivery: benefits, challenges, and recommendations. A consensus report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association [review]. 
    Diabetes care. 2022
  • Continuous glucose monitoring in primary care - are we there [review]?. 
    Current Opinion in Endocrinology, Diabetes, and Obesity. 2022
  • Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis [meta-analysis]. 
    BMJ open diabetes research & care. 2022
  • Primary care and diabetes technologies and treatments [review]. 
    Diabetes Technology & Therapeutics. 2022
  • Comparison of second-generation basal insulin analogs: a review of the evidence from continuous glucose monitoring [review]. 
    Diabetes Technology & Therapeutics. 2021
  • Primary care and diabetes technologies and treatments [review]. 
    Diabetes Technology & Therapeutics. 2021
  • What's wrong with this picture? A critical review of current Centers for Medicare & Medicaid Services coverage criteria for continuous glucose monitoring [review]. 
    Diabetes Technology & Therapeutics. 2021
  • Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group [review]. 
    Diabetes care. 2020
  • HbA1c: the glucose management indicator, time in range, and standardization of continuous glucose monitoring reports in clinical practice [review]. 
    Endocrinology and Metabolism Clinics of North America. 2020
  • The influence of diet interventions using whole, plant food on the gut microbiome: a narrative review [review]. 
    Journal of the Academy of Nutrition and Dietetics. 2020
  • The role of blood glucose monitoring in diabetes management [review]
    2020
  • Advanced technology in the management of diabetes: which comes first-continuous glucose monitor or insulin pump [review]?. 
    Current Diabetes Reports. 2019
  • Advances in technology for management of type 1 diabetes [review]. 
    Lancet (London, England). 2019
  • Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time-in-Range [review]. 
    Diabetes care. 2019
  • Utilizing the ambulatory glucose profile to standardize and implement continuous glucose monitoring in clinical practice [review]. 
    Diabetes Technology & Therapeutics. 2019
  • Approach to using trend arrows in the freestyle libre flash glucose monitoring systems in adults [review]. 
    Journal of the Endocrine Society. 2018
  • Clinical use of continuous glucose monitoring in adults with type 2 diabetes [review]. 
    Diabetes Technology & Therapeutics. 2017
  • Improving the clinical value and utility of CGM systems: issues and recommendations: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group [review]. 
    Diabetologia. 2017
  • Improving the clinical value and utility of CGM systems: issues and recommendations: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group [review]. 
    Diabetes care. 2017
  • International consensus on use of continuous glucose monitoring [review]. 
    Diabetes care. 2017
  • Role of continuous glucose monitoring in clinical trials: recommendations on reporting [review]. 
    Diabetes Technology & Therapeutics. 2017
  • Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [review]. 
    Diabetes care. 2012
  • The safety of incretin-based therapies--review of the scientific evidence [review]. 
    Journal of Clinical Endocrinology and Metabolism. 2011
  • Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications [review]. 
    American Journal of Medicine. 2010
  • Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use [review]. 
    European Journal of Internal Medicine. 2009
  • Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use [review]. 
    American Journal of Medicine. 2009
  • Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association [review]. 
    Journal of the American College of Cardiology. 2009
  • Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association [review]. 
    Circulation. 2009
  • Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association [review]. 
    Diabetes care. 2009
  • A new look at screening and diagnosing diabetes mellitus [review]. 
    Journal of Clinical Endocrinology and Metabolism. 2008
  • Clinical application of emerging sensor technologies in diabetes management: consensus guidelines for continuous glucose monitoring (CGM) [review]. 
    Diabetes Technology & Therapeutics. 2008
  • Diagnosis of insulin resistance and associated syndromes: the spectrum from the metabolic syndrome to type 2 diabetes mellitus [review]. 
    Coronary Artery Disease. 2005
  • The role of self-monitoring of blood glucose in the care of people with diabetes: report of a global consensus conference [review]. 
    American Journal of Medicine. 2005
  • Comprehensive management of patients with type 2 diabetes: establishing priorities of care [review]. 
    American Journal of Managed Care. 2001
  • Intensified diabetes management: lessons from the diabetes control and complications trial [review]. 
    International Journal of Clinical Pharmacology and Therapeutics. 1995
    • Abstract
  • Evaluation of race and ethnicity and pharmacy dispensing of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes [abstract]. 
    Circulation. 2024
  • Change in A1C with and without intermittent use of CGM in adults with type 2 diabetes participating in the Onduo Virtual Diabetes Clinic [abstract]. 
    Diabetes. 2020
  • Cross-study comparisons done right: an illustration using two pivotal trials of closed-loop systems [abstract]. 
    Diabetes. 2020
  • Derived time-in-range is associated with MACE in T2D: data from the DEVOTE Trial [abstract]. 
    Diabetes. 2020
  • First home evaluation of the Omnipod Horizon automated glucose control system at specific glucose targets in children with type 1 diabetes [abstract]. 
    Diabetes. 2020
  • Freestyle Libre system use is associated with reduction in inpatient and outpatient emergency acute diabetes events and all-cause hospitalizations in patients with type 2 diabetes [abstract]. 
    Diabetes. 2020
  • Patient-reported outcomes for 2,335 adults with type 2 diabetes using the omnipod insulin management system show glycemic improvement over first 90 days of use [abstract]. 
    Diabetes. 2020
  • Patients’ interpretation of Ambulatory Glucose Profile (AGP), CGM, and pump reports [abstract]. 
    Diabetes. 2020
  • Safety and glycemic outcomes of the MiniMed advanced hybrid closed-loop (AHCL) system in subjects with T1D [abstract]. 
    Diabetes. 2020
  • Ultra-Rapid Lispro (URLi) demonstrates similar time-in-target range to Humalog with the Medtronic MiniMed 670G Hybrid Closed-Loop System [abstract]. 
    Diabetes. 2020
  • Utilization of continuous glucose monitors is associated with reduction in inpatient and outpatient emergency acute diabetes events regardless of prior blood test strip usage [abstract]. 
    Diabetes. 2020
  • Alogliptin in triple therapy with metformin and sulfonylureas provides significant reductions in HbA1c and is well tolerated: an analysis from the EXAMINE Trial [abstract]. 
    Diabetes. 2016
  • Double-blind mealtime faster-acting insulin aspart vs. insulin aspart in basal-bolus improves glycemic control in T1D: the Onset 1 Trial [abstract #293-OR]. 
    Diabetes. 2016
  • Effect of empagliflozin on nephropathy in subgroups by age: results from EMPA-REG outcome [abstract 1198-P]. 
    Diabetes. 2016
  • Efficacy and safety of LixiLan vs. insulin glargine according to baseline characteristics in patients with type 2 diabetes from the LixiLan-L Trial [abstract 1018-P]. 
    Diabetes. 2016
  • Efficacy and safety of the insulin glargine plus lixisenatide fixed-ratio combination vs. insulin glargine in patients wth T2DM: the LixiLan-L trial [abstract]. 
    Diabetes. 2016
  • Hypoglycemia is associated with increased risk of cardiovascular events: results from the EXAMINE Trial [abstract]. 
    Diabetes. 2016
  • Mortality findings from the EXAMINE Trial [abstract]. 
    Diabetes. 2016
  • Novel pattern identification through standardized data display using the ambulatory glucose profile (AGP) report [abstract]. 
    Diabetes Technology & Therapeutics. 2016
  • Early response to liraglutide 3.0 mg in adults with overweight or obesity and type 2 diabetes: subanalysis of the SCALE Diabetes Trial [abstract]. 
    Diabetes. 2015
  • Glucose variability in type 2 diabetes: the initial results of the FLAT-SUGAR trial [abstract 385-OR]. 
    Diabetes. 2015
  • Glycemic variability correlated with 1.5-anhydroglucitol (1.5 AHG) but not with markers of oxidation, inflammation, and endothelial function: baseline characteristics of the CAROLINA CGM sub-study [abstract]. 
    Diabetes. 2015
  • Hypoglycemia and glucose variability in older adults with type 1 diabetes (T1D) [abstract 408-P]. 
    Diabetes. 2015
  • Major cardiovascular outcomes in the EXAMINE trial according to ACE inhibitor use [abstract]. 
    Diabetes. 2015
  • Superior reduction of HbA1c in a double-blind, randomized study of basal insulin peglispro (BIL) vs. insulin glargine (GL) in patients (pts) with T1D: IMAGINE 3 [abstract]. 
    Diabetes. 2015
  • Trends in diabetes control and insulin use in the U.S., 1998-2010 [abstract]. 
    Diabetes. 2015
  • Understanding patient and clinician glucose reporting preferences in type 1 diabetes: Ambulatory Glucose Profile (AGP) [abstract]. 
    Diabetologia. 2015
    • Audio Document
  • CGM use in type 2 diabetes
    2018
    • Book
  • Management of type 2 diabetes mellitus [health care guideline]
    2006
    • Patent
  • Methods for treating patients with impaired awareness of hypoglycemia
    2021
  • Treatment of hypoglycemia unawareness with intranasal insulin
    2017
    • Webpage
  • Will the surge in new diabetes devices improve patient outcomes?
    2020
    • Quick Info